<?xml version="1.0" encoding="UTF-8"?>
<html xmlns="http://www.w3.org/1999/xhtml">
 <head charset="UTF-8"/>
 <style> * { font-family : helvetica;} .font16 { font-size : 16; } .font17 { font-size : 17; } .font19 { font-size : 19; } .font20 { font-size : 20; } .font21 { font-size : 21; } .font10 { font-size : 10; } .font11 { font-size : 11; } .font12 { font-size : 12; } .font13 { font-size : 13; } .font30 { font-size : 30; } .font14 { font-size : 14; } .font15 { font-size : 15; }</style>
 <body>
  <p>
   <span class="font30">[]. </span>
   <span class="font21">patients </span>
   <span class="font21">COVID- </span>
   <span class="font20">treatment </span>
   <span class="font20">viral </span>
   <span class="font19">virus </span>
   <span class="font17">drug </span>
   <span class="font17">severe </span>
   <span class="font17">clinical </span>
   <span class="font16">SARS-CoV- </span>
   <span class="font16">cell </span>
   <span class="font16">antiviral </span>
   <span class="font15">coronavirus </span>
   <span class="font15">respiratory </span>
   <span class="font15">infection </span>
   <span class="font15">ACE </span>
   <span class="font15">acute </span>
   <span class="font14">combination </span>
   <span class="font14">lung </span>
   <span class="font14">protein </span>
   <span class="font14">human </span>
   <span class="font13">host </span>
   <span class="font13">including </span>
   <span class="font13">influenza </span>
   <span class="font13">syndrome </span>
   <span class="font13">cells </span>
   <span class="font13">enzyme </span>
   <span class="font13">inhibits </span>
   <span class="font13">{border-style </span>
   <span class="font13">RNA </span>
   <span class="font13">[,]. </span>
   <span class="font13">study </span>
   <span class="font13">px;} </span>
   <span class="font13">replication </span>
   <span class="font13">#ffffff;} </span>
   <span class="font13">drugs </span>
   <span class="font13">potential </span>
   <span class="font13">response </span>
   <span class="font13">use </span>
   <span class="font12">cases </span>
   <span class="font12">disease </span>
   <span class="font12">effects </span>
   <span class="font12">inhibitor </span>
   <span class="font12">receptor </span>
   <span class="font12">therapy </span>
   <span class="font12">used </span>
   <span class="font12">azithromycin </span>
   <span class="font12">protease </span>
   <span class="font12">Oral </span>
   <span class="font12">entry </span>
   <span class="font12">inhibitors </span>
   <span class="font12">reported </span>
   <span class="font12">shown </span>
   <span class="font12">trials </span>
   <span class="font12">type </span>
   <span class="font12">activity </span>
   <span class="font12">adverse </span>
   <span class="font12">effect </span>
   <span class="font12">expression </span>
   <span class="font12">novel </span>
   <span class="font12">suggested </span>
   <span class="font12">However, </span>
   <span class="font12">active </span>
   <span class="font12">associated </span>
   <span class="font12">infected </span>
   <span class="font12">trial </span>
   <span class="font12">viruses </span>
   <span class="font11">Agents </span>
   <span class="font11">Ivermectin </span>
   <span class="font11">Known </span>
   <span class="font11">SARS-CoV </span>
   <span class="font11">binding </span>
   <span class="font11">immune </span>
   <span class="font11">inflammatory </span>
   <span class="font11">... </span>
   <span class="font11">IL- </span>
   <span class="font11">Inhibits </span>
   <span class="font11">expected </span>
   <span class="font11">inhibit </span>
   <span class="font11">membrane </span>
   <span class="font11">role </span>
   <span class="font11">safety </span>
   <span class="font11">virus, </span>
   <span class="font11">Infect. </span>
   <span class="font11">Intravenous </span>
   <span class="font11">PD- </span>
   <span class="font11">death </span>
   <span class="font11">effective </span>
   <span class="font11">efficacy </span>
   <span class="font11">elevated </span>
   <span class="font11">include </span>
   <span class="font11">increased </span>
   <span class="font11">infection, </span>
   <span class="font11">interaction </span>
   <span class="font11">lopinavir/ritonavir </span>
   <span class="font11">pulmonary </span>
   <span class="font11">reactions </span>
   <span class="font11">registered </span>
   <span class="font11">review </span>
   <span class="font11">risk </span>
   <span class="font11">spike </span>
   <span class="font11">(NCT). </span>
   <span class="font11">COVID-, </span>
   <span class="font11">Clinical </span>
   <span class="font11">East </span>
   <span class="font11">allergic </span>
   <span class="font11">analysis </span>
   <span class="font11">angiotensin </span>
   <span class="font11">antibody </span>
   <span class="font11">baricitinib </span>
   <span class="font11">binds </span>
   <span class="font11">case </span>
   <span class="font11">cellular </span>
   <span class="font11">complex </span>
   <span class="font11">early </span>
   <span class="font11">hydroxychloroquine </span>
   <span class="font11">injury </span>
   <span class="font11">key </span>
   <span class="font11">mechanism </span>
   <span class="font11">oseltamivir </span>
   <span class="font11">px; </span>
   <span class="font11">receptors </span>
   <span class="font11">release </span>
   <span class="font11">rheumatoid </span>
   <span class="font11">sepsis </span>
   <span class="font11">studies </span>
   <span class="font11">viruses. </span>
   <span class="font11">{font-family </span>
   <span class="font11">April </span>
   <span class="font11">FDA </span>
   <span class="font11">Health </span>
   <span class="font11">JAK </span>
   <span class="font11">Med. </span>
   <span class="font11">Middle </span>
   <span class="font11">TMPRSS </span>
   <span class="font11">[], </span>
   <span class="font11">addition </span>
   <span class="font11">agents </span>
   <span class="font11">approved </span>
   <span class="font11">care </span>
   <span class="font11">chloroquine </span>
   <span class="font11">currently </span>
   <span class="font11">dengue </span>
   <span class="font11">development </span>
   <span class="font11">effectiveness </span>
   <span class="font11">endocytosis </span>
   <span class="font11">epithelial </span>
   <span class="font11">font-size </span>
   <span class="font11">https://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font11">hypersensitivity </span>
   <span class="font11">infection. </span>
   <span class="font11">infections </span>
   <span class="font11">interferon </span>
   <span class="font11">ivermectin </span>
   <span class="font11">kinase </span>
   <span class="font11">levels </span>
   <span class="font11">new </span>
   <span class="font11">online: </span>
   <span class="font11">phase </span>
   <span class="font11">remdesivir </span>
   <span class="font11">renal </span>
   <span class="font11">specific </span>
   <span class="font11">surface </span>
   <span class="font11">therapies </span>
   <span class="font11">.collab: </span>
   <span class="font11">ALT/AST </span>
   <span class="font11">COVID-. </span>
   <span class="font11">Engl. </span>
   <span class="font11">HCQ </span>
   <span class="font11">HIV- </span>
   <span class="font11">Interestingly, </span>
   <span class="font11">MERS-CoV </span>
   <span class="font11">Oseltamivir </span>
   <span class="font11">QTc </span>
   <span class="font11">SARS </span>
   <span class="font11">SARS-CoV-. </span>
   <span class="font11">Thus, </span>
   <span class="font11">activation </span>
   <span class="font11">anti-inflammatory </span>
   <span class="font11">camostat </span>
   <span class="font11">cytokine </span>
   <span class="font11">days </span>
   <span class="font11">distress </span>
   <span class="font11">double; </span>
   <span class="font11">e.g., </span>
   <span class="font11">higher </span>
   <span class="font11">important </span>
   <span class="font11">inhibiting </span>
   <span class="font11">inhibition </span>
   <span class="font11">intravenous </span>
   <span class="font11">investigation </span>
   <span class="font11">leading </span>
   <span class="font11">liver </span>
   <span class="font11">major </span>
   <span class="font11">mild </span>
   <span class="font11">monoclonal </span>
   <span class="font11">pathway </span>
   <span class="font11">pathways </span>
   <span class="font11">plasma </span>
   <span class="font11">potent </span>
   <span class="font11">previous </span>
   <span class="font11">showed </span>
   <span class="font11">significant </span>
   <span class="font11">targeting </span>
   <span class="font11">therapeutic </span>
   <span class="font11">treated </span>
   <span class="font11">various </span>
   <span class="font10">ANGII </span>
   <span class="font10">ATR </span>
   <span class="font10">Antiviral </span>
   <span class="font10">Baricitinib </span>
   <span class="font10">CYPA </span>
   <span class="font10">Camrelizumab </span>
   <span class="font10">Care </span>
   <span class="font10">China </span>
   <span class="font10">Currently, </span>
   <span class="font10">Janus </span>
   <span class="font10">Med../NEJMoa </span>
   <span class="font10">Non-significant </span>
   <span class="font10">Patients </span>
   <span class="font10">Remdesivir </span>
   <span class="font10">Severe </span>
   <span class="font10">Table </span>
   <span class="font10">Treatment </span>
   <span class="font10">acid </span>
   <span class="font10">addition, </span>
   <span class="font10">angiotensin-converting </span>
   <span class="font10">available </span>
   <span class="font10">blood </span>
   <span class="font10">border-color </span>
   <span class="font10">border-width </span>
   <span class="font10">cause </span>
   <span class="font10">critically </span>
   <span class="font10">cytokines </span>
   <span class="font10">decrease </span>
   <span class="font10">developed </span>
   <span class="font10">developing </span>
   <span class="font10">different </span>
   <span class="font10">dose </span>
   <span class="font10">enhance </span>
   <span class="font10">events </span>
   <span class="font10">failure </span>
   <span class="font10">function </span>
   <span class="font10">heart </span>
   <span class="font10">hospitalized </span>
   <span class="font10">humanized </span>
   <span class="font10">ill </span>
   <span class="font10">immunoglobulins </span>
   <span class="font10">included </span>
   <span class="font10">infections, </span>
   <span class="font10">investigated </span>
   <span class="font10">known </span>
   <span class="font10">lopinavir </span>
   <span class="font10">low </span>
   <span class="font10">management </span>
   <span class="font10">medications </span>
   <span class="font10">mesylate </span>
   <span class="font10">mortality </span>
   <span class="font10">patients. </span>
   <span class="font10">polymerase </span>
   <span class="font10">possible </span>
   <span class="font10">proteins </span>
   <span class="font10">rapid </span>
   <span class="font10">rate </span>
   <span class="font10">recent </span>
   <span class="font10">recently </span>
   <span class="font10">recombinant </span>
   <span class="font10">reduce </span>
   <span class="font10">reduction </span>
   <span class="font10">responses </span>
   <span class="font10">ritonavir </span>
   <span class="font10">screening </span>
   <span class="font10">small </span>
   <span class="font10">solid; </span>
   <span class="font10">tocilizumab </span>
   <span class="font10">treat </span>
   <span class="font10">tuberculosis </span>
   <span class="font10">using </span>
   <span class="font10">{font-style </span>
   <span class="font10">{font-weight </span>
   <span class="font10">&amp;lt; </span>
   <span class="font10">(NCT </span>
   <span class="font10">ACEi </span>
   <span class="font10">ARB </span>
   <span class="font10">Bevacizumab </span>
   <span class="font10">ChiCTR). </span>
   <span class="font10">Chinese </span>
   <span class="font10">Clin. </span>
   <span class="font10">Drug </span>
   <span class="font10">Ebola </span>
   <span class="font10">Figure </span>
   <span class="font10">Fingolimod </span>
   <span class="font10">GIT </span>
   <span class="font10">HN, </span>
   <span class="font10">Hypersensitivity </span>
   <span class="font10">IL-, </span>
   <span class="font10">Meplazumab </span>
   <span class="font10">Moreover, </span>
   <span class="font10">PD-L </span>
   <span class="font10">Pregnancy </span>
   <span class="font10">RNA-dependent </span>
   <span class="font10">Res../j.antiviral... </span>
   <span class="font10">Respir. </span>
   <span class="font10">Rev. </span>
   <span class="font10">Ribavirin </span>
   <span class="font10">Ruxolitinib </span>
   <span class="font10">T-cells </span>
   <span class="font10">Virol../JVI.- </span>
   <span class="font10">Wuhan, </span>
   <span class="font10">agent </span>
   <span class="font10">agent, </span>
   <span class="font10">al.A </span>
   <span class="font10">analog </span>
   <span class="font10">and, </span>
   <span class="font10">antibodies </span>
   <span class="font10">asthenia, </span>
   <span class="font10">based </span>
   <span class="font10">benefit </span>
   <span class="font10">block </span>
   <span class="font10">blocking </span>
   <span class="font10">bold </span>
   <span class="font10">broad </span>
   <span class="font10">broad-spectrum </span>
   <span class="font10">causes </span>
   <span class="font10">cells, </span>
   <span class="font10">chance </span>
   <span class="font10">clearance </span>
   <span class="font10">combined </span>
   <span class="font10">common </span>
   <span class="font10">compared </span>
   <span class="font10">computational </span>
   <span class="font10">concentration </span>
   <span class="font10">control </span>
   <span class="font10">courier; </span>
   <span class="font10">data </span>
   <span class="font10">diseases </span>
   <span class="font10">dysfunction </span>
   <span class="font10">em; </span>
   <span class="font10">endothelial </span>
   <span class="font10">enzymes </span>
   <span class="font10">essential </span>
   <span class="font10">evidence </span>
   <span class="font10">favipiravir </span>
   <span class="font10">fusion </span>
   <span class="font10">hand, </span>
   <span class="font10">healthy </span>
   <span class="font10">high </span>
   <span class="font10">https://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCThttps://clinicaltrials.gov/ct/show/NCT </span>
   <span class="font10">immunoglobulin </span>
   <span class="font10">importin </span>
   <span class="font10">induced </span>
   <span class="font10">inflammation </span>
   <span class="font10">inhibitor. </span>
   <span class="font10">interactions </span>
   <span class="font10">interleukin- </span>
   <span class="font10">lead </span>
   <span class="font10">leads </span>
   <span class="font10">metabolism </span>
   <span class="font10">molecule </span>
   <span class="font10">multiple </span>
   <span class="font10">myocardial </span>
   <span class="font10">myocarditis </span>
   <span class="font10">neuraminidase </span>
   <span class="font10">neuropsychiatric </span>
   <span class="font10">neutralizing </span>
   <span class="font10">nuclear </span>
   <span class="font10">number </span>
   <span class="font10">organ </span>
   <span class="font10">pharmacological </span>
   <span class="font10">prevent </span>
   <span class="font10">preventing </span>
   <span class="font10">previously </span>
   <span class="font10">pro-inflammatory </span>
   <span class="font10">production </span>
   <span class="font10">proteins. </span>
   <span class="font10">pt;} </span>
   <span class="font10">rapidly </span>
   <span class="font10">reports </span>
   <span class="font10">repurposed </span>
   <span class="font10">required </span>
   <span class="font10">results </span>
   <span class="font10">ribavirin </span>
   <span class="font10">safe </span>
   <span class="font10">serine </span>
   <span class="font10">slow </span>
   <span class="font10">spread </span>
   <span class="font10">support </span>
   <span class="font10">symptoms </span>
   <span class="font10">syndrome- </span>
   <span class="font10">synthesis </span>
   <span class="font10">target </span>
   <span class="font10">tested </span>
   <span class="font10">vascular </span>
  </p>
 </body>
</html>
